Latest Insider Transactions at Sarepta Therapeutics, Inc. (SRPT)
This section provides a real-time view of insider transactions for Sarepta Therapeutics, Inc. (SRPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sarepta Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sarepta Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2022
|
Kathryn Jean Boor |
BUY
Grant, award, or other acquisition
|
Direct |
4,908
+50.0%
|
-
|
|
Jun 01
2022
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
54
-0.21%
|
$3,888
$72.67 P/Share
|
|
Mar 07
2022
|
Stephen Mayo |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+28.96%
|
-
|
|
Mar 07
2022
|
Richard Barry |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+0.1%
|
-
|
|
Mar 07
2022
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+2.09%
|
-
|
|
Mar 07
2022
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+13.17%
|
-
|
|
Mar 07
2022
|
Mary Ann Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+19.29%
|
-
|
|
Mar 07
2022
|
Claude Nicaise |
BUY
Grant, award, or other acquisition
|
Direct |
2,953
+16.63%
|
-
|
|
Mar 07
2022
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+9.99%
|
-
|
|
Mar 07
2022
|
William Ciambrone EVP |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+26.58%
|
-
|
|
Mar 07
2022
|
Ryan Edward Brown EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+23.6%
|
-
|
|
Mar 07
2022
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
153
-0.85%
|
$12,087
$79.36 P/Share
|
|
Mar 07
2022
|
Ian Michael Estepan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+19.67%
|
-
|
|
Mar 07
2022
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-1.59%
|
$31,442
$79.36 P/Share
|
|
Mar 04
2022
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,216
-1.86%
|
$96,064
$79.2 P/Share
|
|
Mar 04
2022
|
William Ciambrone EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
1,160
-7.6%
|
$91,640
$79.2 P/Share
|
|
Mar 04
2022
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,136
-5.92%
|
$89,744
$79.2 P/Share
|
|
Mar 04
2022
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,308
-4.96%
|
$103,332
$79.2 P/Share
|
|
Mar 01
2022
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
184
-0.95%
|
$13,800
$75.05 P/Share
|
|
Mar 01
2022
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
376
-1.41%
|
$28,200
$75.05 P/Share
|
|
Mar 01
2022
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.87%
|
$42,900
$75.05 P/Share
|
|
Dec 15
2021
|
M Kathleen Behrens |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.56%
|
$50,000
$10.08 P/Share
|
|
Dec 10
2021
|
Mary Ann Gray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
967
+9.33%
|
-
|
|
Nov 24
2021
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Open market or private purchase
|
Direct |
3,780
+5.44%
|
$298,620
$79.33 P/Share
|
|
Nov 17
2021
|
Douglas S Ingram President & CEO |
BUY
Open market or private purchase
|
Direct |
25,026
+6.42%
|
$1,977,054
$79.94 P/Share
|
|
Nov 16
2021
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+39.25%
|
-
|
|
Nov 16
2021
|
Stephen Mayo |
BUY
Grant, award, or other acquisition
|
Direct |
4,292
+50.0%
|
-
|
|
Sep 08
2021
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,623
-5.72%
|
$126,594
$78.29 P/Share
|
|
Jun 26
2021
|
Douglas S Ingram President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,812
-4.98%
|
$1,424,960
$80.4 P/Share
|
|
Jun 01
2021
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-0.33%
|
$4,864
$76.01 P/Share
|
|
Mar 10
2021
|
M Kathleen Behrens |
SELL
Open market or private sale
|
Direct |
5,000
-3.69%
|
$425,000
$85.76 P/Share
|
|
Mar 10
2021
|
M Kathleen Behrens |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.56%
|
$210,000
$42.3 P/Share
|
|
Mar 08
2021
|
Hans Lennart Rudolf Wigzell |
SELL
Open market or private sale
|
Direct |
10,000
-37.71%
|
$830,000
$83.51 P/Share
|
|
Mar 08
2021
|
Hans Lennart Rudolf Wigzell |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+27.38%
|
$340,000
$34.92 P/Share
|
|
Mar 03
2021
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
2,726
+2.05%
|
-
|
|
Mar 03
2021
|
Richard Barry |
BUY
Grant, award, or other acquisition
|
Direct |
2,726
+0.09%
|
-
|
|
Mar 03
2021
|
Ryan Edward Brown EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+43.06%
|
-
|
|
Mar 03
2021
|
William Ciambrone EVP |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Mar 03
2021
|
Ian Michael Estepan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+34.06%
|
-
|
|
Mar 03
2021
|
Mary Ann Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,726
+24.42%
|
-
|
|
Mar 03
2021
|
John C Martin Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,726
+25.62%
|
-
|
|
Mar 03
2021
|
Claude Nicaise |
BUY
Grant, award, or other acquisition
|
Direct |
2,726
+18.7%
|
-
|
|
Mar 03
2021
|
Gilmore Neil O'Neill EVP, R&D & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+34.04%
|
-
|
|
Mar 03
2021
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+40.36%
|
-
|
|
Mar 03
2021
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
2,726
+14.17%
|
-
|
|
Dec 31
2020
|
Douglas S Ingram President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,144
-9.4%
|
$6,314,480
$170.49 P/Share
|
|
Dec 11
2020
|
Joseph Bratica Principal Financial Officer |
SELL
Open market or private sale
|
Direct |
1,115
-12.05%
|
$183,975
$165.0 P/Share
|
|
Dec 11
2020
|
Joseph Bratica Principal Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,115
+10.75%
|
$79,165
$71.45 P/Share
|
|
Dec 10
2020
|
Mary Ann Gray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
967
+14.48%
|
-
|
|
Dec 08
2020
|
Joseph Bratica Principal Financial Officer |
SELL
Open market or private sale
|
Direct |
1,125
-12.14%
|
$180,000
$160.0 P/Share
|